Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fish and Richardson
McKinsey
Federal Trade Commission
AstraZeneca
Cantor Fitzgerald
Boehringer Ingelheim
Argus Health
McKesson

Generated: May 26, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,753,789

« Back to Dashboard

Summary for Patent: 4,753,789
Title: Method for treating nausea and vomiting
Abstract:The invention relates to the use of compounds of the general formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycoalkyl-(C.sub.1-4) alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group, and one of the groups represented by R.sup.2,R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl - C.sub.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage of radiological examination procedures. The invention also relates to a product containing a therapeutic agent liable to induce nausea and vomiting, e.g. a cytostatic agent such as a cyclophosphamide, an alkylating agent or a platinum complex, and a compound of the general formula (I) as a combined preparation for simultaneous separate or sequential use in therapy.
Inventor(s): Tyers; Michael B. (Welwyn, GB2), Coates; Ian H. (Hertford, GB2), Humber; David C. (London, GB2), Ewan; George B. (Gerrards Cross, GB2), Bell; James A. (Royston, GB2)
Assignee: Glaxo Group Limited (GB2)
Application Number:06/877,805
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 4,753,789
Patent Claims: 1. A method of treatment for the relief of nausea and vomiting which comprises administering to a human or animal subject in need thereof an effective amount for treatment for the relief of nausea and vomiting of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one or a physiologically acceptable salt or solvate thereof.

2. A method according to claim 1 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride.

3. A method according to claim 1 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

4. A method according to claim 1 wherein said nausea and vomiting is induced by an anticancer drug.

5. A method according to claim 4 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

6. A method according to claim 4 wherein said anticancer drug is a cytostatic agent.

7. A method according to claim 6 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

8. A method according to claim 4 wherein said nausea and vomiting is induced by a platinum complex.

9. A method according to claim 8 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

10. A method according to claim 4 wherein said nausea and vomiting is induced by cisplatin.

11. A method according to claim 10 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1)methyl]-4H-carbazol -4-one is in the form of its hydrochloride dihydrate.

12. A method according to claim 1 wherein said nausea and vomiting is induced by an alkylating agent.

13. A method according to claim 1 wherein said nausea and vomiting is induced by cyclophosphamide.

14. A method according to claim 12 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

15. A method according to claim 13 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

16. A method according to claim 1 wherein said nausea and vomiting is induced by radiation.

17. A method according to claim 16 wherein the 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one is in the form of its hydrochloride dihydrate.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
Medtronic
Deloitte
UBS
Fuji
Federal Trade Commission
Julphar
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.